{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:52:54Z","timestamp":1790103174439,"version":"4.0.1"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00467-008-0789-y","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T12:28:57Z","timestamp":1205238537000},"page":"705-716","source":"Crossref","is-referenced-by-count":87,"title":["Therapeutic strategies to slow chronic kidney disease progression"],"prefix":"10.1007","volume":"23","author":[{"given":"Elke","family":"W\u00fchl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"789_CR1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1542\/peds.111.4.e382","volume":"111","author":"G Ardissino","year":"2003","unstructured":"Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, Marra G, Edefonti A, Sereni F (2003) Epidemiology of chronic renal failure in children: data from the ItalKid Project. Pediatrics 111:382\u2013387","journal-title":"Pediatrics"},{"key":"789_CR2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00467-007-0459-5","volume":"7","author":"C Gonz\u00e1lez Celed\u00f3n","year":"2007","unstructured":"Gonz\u00e1lez Celed\u00f3n C, Bitsori M, Tullus K (2007) Progression of chronic renal failure in children with dysplastic kidneys. Pediatr Nephrol 7:1014\u201320","journal-title":"Pediatr Nephrol"},{"key":"789_CR3","first-page":"180","volume":"13","author":"MJ Klag","year":"1996","unstructured":"Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J (1996) Blood pressure and end-stage renal disease in men. Hypertension 13:180\u2013193","journal-title":"Hypertension"},{"key":"789_CR4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","volume":"63","author":"K Iseki","year":"2003","unstructured":"Iseki K, Ikemiya Y, Iseki C, Takishita S (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63:1468\u20131474","journal-title":"Kidney Int"},{"key":"789_CR5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/oxfordjournals.ndt.a027312","volume":"11","author":"F Locatelli","year":"1996","unstructured":"Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli B, Giangrande A (1996) Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 11:461\u2013467","journal-title":"Nephrol Dial Transplant"},{"key":"789_CR6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1399-3046.2005.00468.x","volume":"10","author":"T Seeman","year":"2006","unstructured":"Seeman T, Simkova E, Kreisinger J, Vondrak K, Dusek J, Gilik J, Feber J, Dvorak P, Janda J (2006) Control of hypertension in children after renal transplantation. Pediatr Transplant 10:316\u2013322","journal-title":"Pediatr Transplant"},{"key":"789_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s004670050226","volume":"11","author":"N Lingens","year":"1997","unstructured":"Lingens N, Dobos E, Witte K, Busch C, Lemmer B, Klaus G, Sch\u00e4rer K (1997) Twenty-four-hour ambulatory blood pressure profiles in pediatric patients after renal transplantation. Pediatr Nephrol 11:23\u201326","journal-title":"Pediatr Nephrol"},{"key":"789_CR8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/978-1-59259-797-0_21","volume-title":"Pediatric Hypertension","author":"Franz Schaefer","year":"2004","unstructured":"Schaefer F, Mehls O (2004) Hypertension in chronic kidney disease. In: Portman RJ, Sorof JM, Ingelfinger JR (eds) Pediatric hypertension. Humana Press, Totowa, pp 371\u2013387"},{"key":"789_CR9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(96)09260-4","volume":"349","author":"AM Wingen","year":"1997","unstructured":"Wingen AM, Fabian-Bach C, Schaefer F, Mehls O (1997) Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European study group of nutritional treatment of chronic renal failure in childhood. Lancet 349:1117\u20131123","journal-title":"Lancet"},{"key":"789_CR10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","volume":"36","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Williams M, Dworkin L, Elliot WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am J Kidney Dis 36:646\u2013661","journal-title":"Am J Kidney Dis"},{"key":"789_CR11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:754\u2013762","journal-title":"Ann Intern Med"},{"key":"789_CR12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","volume":"142","author":"MJ Sarnak","year":"2005","unstructured":"Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS (2005) The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142:342\u2013351","journal-title":"Ann Intern Med"},{"key":"789_CR13","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Barkis GL, Black DL, Cushman WC, Green LA, Izzo JLJ, Jones DW, Materson BJ, Oparil S, Wright JTJ, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. JAMA 289:2560\u20132571","journal-title":"JAMA"},{"key":"789_CR14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"Guidelines for the Management of Arterial Hypertension","year":"2007","unstructured":"Guidelines for the Management of Arterial Hypertension (2007) The task force of the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 25:1105\u20131187","journal-title":"J Hypertens"},{"key":"789_CR15","first-page":"S1","volume":"43","author":"Kidney Disorder Outcomes Quality Initiative (K\/DOQI)","year":"2004","unstructured":"Kidney Disorder Outcomes Quality Initiative (K\/DOQI) (2004) K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43:S1\u2013S290","journal-title":"Am J Kidney Dis"},{"key":"789_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1542\/peds.114.2.S2.555","volume":"114","author":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","unstructured":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555\u2013576","journal-title":"Pediatrics"},{"key":"789_CR17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1523-1755.2004.00802.x","volume":"66","author":"E W\u00fchl","year":"2004","unstructured":"W\u00fchl E, Mehls O, Schaefer F, ESCAPE trial group (2004) Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 66:768\u2013776","journal-title":"Kidney Int"},{"key":"789_CR18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/sj.jhh.1001734","volume":"18","author":"P Jacob","year":"2004","unstructured":"Jacob P, Hartung R, Bohlender J, Stein G (2004) Utility of 24-h ambulatory blood pressure measurement in a routine clinical setting of patients with chronic renal disease. J Hum Hypertens 18:745\u2013751","journal-title":"J Hum Hypertens"},{"key":"789_CR19","first-page":"382","volume":"43","author":"M Timio","year":"1995","unstructured":"Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, Guerrini E (1995) \u2018Non-dipper\u2019 hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 43:382\u2013387","journal-title":"Clin Nephrol"},{"key":"789_CR20","first-page":"168A","volume":"11","author":"M Tarver-Carr","year":"2000","unstructured":"Tarver-Carr M, Brancati F, Eberhardt M, Powe N (2000) Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J Am Soc Nephrol 11:168A","journal-title":"J Am Soc Nephrol"},{"key":"789_CR21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1523-1755.2001.00792.x","volume":"60","author":"WE Hoy","year":"2001","unstructured":"Hoy WE, Wang Z, vanBuynder P, Baker PR, Mathews JD (2001) The natural history of renal disease in Autralian aborigines. Part I. Changes in albuminuria and glomerular filtration rate over time. Kidney Int 60:243\u2013248","journal-title":"Kidney Int"},{"key":"789_CR22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0272-6386(04)01080-7","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Kinjo K, Iseki C, Takishita S (2004) Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 44:806\u2013814","journal-title":"Am J Kidney Dis"},{"key":"789_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(68)90589-8","volume":"2","author":"RA Risdon","year":"1968","unstructured":"Risdon RA, Sloper JC, de Wardener HE (1968) Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet 2:363\u2013366","journal-title":"Lancet"},{"key":"789_CR24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-136-8-200204160-00010","volume":"136","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi G, Ruggenenti P, Perico N (2002) Chronic renal disease: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136:604\u2013615","journal-title":"Ann Intern Med"},{"key":"789_CR25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"JC Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter LJ (1995) Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study. Ann Intern Med 123:754\u2013762","journal-title":"Ann Intern Med"},{"key":"789_CR26","first-page":"S54","volume":"63","author":"P Ruggenenti","year":"1997","unstructured":"Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G (1997) Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The \u201cGruppo Italiano di Studi Epidemiologici in Nefrologia\u201d (GISEN). Kidney Int Suppl 63:S54\u2013S57","journal-title":"Kidney Int Suppl"},{"key":"789_CR27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00467-003-1268-0","volume":"19","author":"G Ardissino","year":"2004","unstructured":"Ardissino G, Testa S, Dacco V, Vigano S, Taioli E, Claris-Appiani A, Procaccio M, Avolio L, Ciofani A, Dello Strologo L, Montini G (2004) Proteinuria as a predictor of disease progression in children with hypodysplastic nephropathy. Pediatr Nephrol 19:172\u2013177","journal-title":"Pediatr Nephrol"},{"key":"789_CR28","first-page":"1505","volume":"21","author":"E W\u00fchl","year":"2006","unstructured":"W\u00fchl E, Mehls O, Schaefer F, ESCAPE trial group (2006) Long-term dissociation of antiproteinuric and antihypertensive efficacy of ACE inhibition in children with chronic renal failure. Pediatr Nephrol 21:1505 (Abstract COD. OC 16)","journal-title":"Pediatr Nephrol"},{"key":"789_CR29","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1542\/peds.105.6.1242","volume":"105","author":"RJ Hogg","year":"2000","unstructured":"Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: Recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105:1242\u20131249","journal-title":"Pediatrics"},{"key":"789_CR30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00467-003-1329-4","volume":"19","author":"M Litwin","year":"2004","unstructured":"Litwin M (2004) Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol 19:178\u2013186","journal-title":"Pediatr Nephrol"},{"key":"789_CR31","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857\u20131863","journal-title":"Lancet"},{"key":"789_CR32","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2003","unstructured":"Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG (2003) African American study of kidney disease and hypertension: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288:2421\u20132431","journal-title":"JAMA"},{"key":"789_CR33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ki.1997.2","volume":"51","author":"G Remuzzi","year":"1997","unstructured":"Remuzzi G, Ruggenenti P, Benigni A (1997) Understanding the nature of renal disease progression. Kidney Int 51:2\u201315","journal-title":"Kidney Int"},{"key":"789_CR34","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","volume":"63","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Perna A, Remuzzi G (2003) Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63:2254\u20132261","journal-title":"Kidney Int"},{"key":"789_CR35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, Giatras J, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, DeJong P, DeZeeuw D, Lau J, Levey AS; ACE inhibition in progressive renal disease study group (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73\u201387","journal-title":"Ann Intern Med"},{"key":"789_CR36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","volume":"357","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, Schieppati A, Remuzzi G (2001) Progression, remission, regression of chronic renal diseases. Lancet 357:1601\u20131608","journal-title":"Lancet"},{"key":"789_CR37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","volume":"58","author":"P Muntner","year":"2000","unstructured":"Muntner P, Coresh J, Clinton Smith J, Eckfeldt J, Klag MJ (2000) Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58:293\u2013301","journal-title":"Kidney Int"},{"key":"789_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00008480-200204000-00009","volume":"14","author":"MJ Saland","year":"2002","unstructured":"Saland MJ, Ginsberg H, Fisher EA (2002) Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. Curr Opin Pediatr 14:197\u2013204","journal-title":"Curr Opin Pediatr"},{"key":"789_CR39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000075925","volume":"24","author":"CK Abrass","year":"2004","unstructured":"Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46\u201353","journal-title":"Am J Nephrol"},{"key":"789_CR40","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1046\/j.1523-1755.1999.07112.x","volume":"71","author":"M Hattori","year":"1999","unstructured":"Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkins RC, Kawaguchi H, Ito K (1999) Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl 71:S47\u2013S50","journal-title":"Kidney Int Suppl"},{"key":"789_CR41","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0140-6736(90)93090-C","volume":"335","author":"H Mulec","year":"1990","unstructured":"Mulec H, Johnson SA, Bjorck S (1990) Relation between serum cholesterol and diabetic nephropathy. Lancet 335:1537\u20131538","journal-title":"Lancet"},{"key":"789_CR42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-140-3-200402030-00007","volume":"140","author":"J Chen","year":"2004","unstructured":"Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J (2004) The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140:167\u2013174","journal-title":"Ann Intern Med"},{"key":"789_CR43","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1681\/ASN.V133806","volume":"13","author":"DH Kang","year":"2002","unstructured":"Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ (2002) Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13:806\u2013816","journal-title":"J Am Soc Nephrol"},{"key":"789_CR44","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ki.1997.377","volume":"52","author":"C Orphanides","year":"1997","unstructured":"Orphanides C, Fine LG, Norman JT (1997) Hypoxia stimulates proximal tubular cell matrix production via a TGF-\u00df1-independent mechanism. Kidney Int 52:637\u2013647","journal-title":"Kidney Int"},{"key":"789_CR45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/sj.ki.5002483","volume":"72","author":"Z Aydin","year":"2007","unstructured":"Aydin Z, Duijs J, Bajerna IM, van Zonneveld AJ, Rabelink TJ (2007) Erythropoietin, progenitors, and repair. Kidney Int 72:516\u2013520","journal-title":"Kidney Int"},{"key":"789_CR46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000112413","volume":"28","author":"I Karamouzis","year":"2008","unstructured":"Karamouzis I, Sarafidis PA, Karamouzis M, Illiadis S, Haidich A-M, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM (2008) Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 28:397\u2013404","journal-title":"Am J Nephrol"},{"key":"789_CR47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/BF00852539","volume":"7","author":"P Baudoin","year":"1993","unstructured":"Baudoin P, Provoost AP (1993) Effects of age at the time of unilateral nephrectomy and dietary protein on long-term renal function in rats. Pediatr Nephrol 7:536\u2013542","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 99","key":"789_CR48","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1111\/j.1523-1755.2005.09912.x","volume":"68","author":"E Ritz","year":"2005","unstructured":"Ritz E, Gross ML, Dikow R (2005) Role of calcium-phosphorous disorders in the progression of renal failure. Kidney Int 68(Suppl 99):S66\u2013S70","journal-title":"Kidney Int"},{"key":"789_CR49","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","volume":"61","author":"RW Schrier","year":"2002","unstructured":"Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of agressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086\u20131097","journal-title":"Kidney Int"},{"key":"789_CR50","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Sanpinn SM, Zhan Z, Shahinfar S, RENAAL study investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"789_CR51","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Raymond PB, Rohde RD; Collaborative Study Group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456\u20131462","journal-title":"N Engl J Med"},{"key":"789_CR52","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1681\/ASN.2005050522","volume":"16","author":"Y Izuhara","year":"2005","unstructured":"Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T (2005) Renoprotective properties of antiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 16:3631\u20133641","journal-title":"J Am Soc Nephrol"},{"key":"789_CR53","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939\u2013945","journal-title":"N Engl J Med"},{"key":"789_CR54","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(83)92462-5","volume":"1","author":"HH Parving","year":"1983","unstructured":"Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175\u20131179","journal-title":"Lancet"},{"key":"789_CR55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ki.1992.309","volume":"42","author":"P Zucchelli","year":"1992","unstructured":"Zucchelli P, Zuccal\u00e0 A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R (1992) Long-term comparison between captopril and nifidepine in the progression of renal insufficiency. Kidney Int 42:452\u2013458","journal-title":"Kidney Int"},{"key":"789_CR56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","volume":"5","author":"AL Kamper","year":"1992","unstructured":"Kamper AL, Strandgaard S, Leyssac P (1992) Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial. Am J Hypertens 5:423\u2013430","journal-title":"Am J Hypertens"},{"key":"789_CR57","first-page":"S58","volume":"63","author":"GG Essen van","year":"1997","unstructured":"van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D (1997) Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 63:S58\u2013S62","journal-title":"Kidney Int Suppl"},{"key":"789_CR58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","volume":"309","author":"T Hannedouche","year":"1994","unstructured":"Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suo JM, Grunfeld JP (1994) Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833\u2013837","journal-title":"BMJ"},{"key":"789_CR59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000423895","volume":"111","author":"KM Bannister","year":"1995","unstructured":"Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ (1995) Effect of angiotensin converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 111:184\u2013192","journal-title":"Contrib Nephrol"},{"key":"789_CR60","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0272-6386(96)90158-4","volume":"27","author":"BU Ihle","year":"1996","unstructured":"Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ (1996) Angiotensin-converting-enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 27:489\u2013495","journal-title":"Am J Kidney Dis"},{"key":"789_CR61","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","volume":"354","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Gherardi G, Garini G, Zocalli C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359\u2013364","journal-title":"Lancet"},{"key":"789_CR62","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","volume":"271","author":"G Viberti","year":"1994","unstructured":"Viberti G, Mogensen CE, Groop LC, Pauls JF (1994) Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European microalbuminuria captopril study group. JAMA 271:275\u2013279","journal-title":"JAMA"},{"key":"789_CR63","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/bmj.297.6656.1086","volume":"297","author":"HH Parving","year":"1988","unstructured":"Parving HH, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ 297:1086\u20131091","journal-title":"BMJ"},{"key":"789_CR64","first-page":"117\u2014124","volume":"361","author":"N Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117\u2014124","journal-title":"Lancet"},{"key":"789_CR65","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics exposed to telmisartan and enalapril study group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952\u20131961","journal-title":"N Engl J Med"},{"key":"789_CR66","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Weiliang C, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026\u20132033","journal-title":"Lancet"},{"key":"789_CR67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199002000-00015","volume":"15","author":"V Mooser","year":"1990","unstructured":"Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR (1990) Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 15:276\u2013282","journal-title":"J Cardiovasc Pharmacol"},{"key":"789_CR68","first-page":"803","volume":"10","author":"AH Meiracker van den","year":"1992","unstructured":"van den Meiracker AH, Man in\u2019t Veld AJ, Admiraal PJ, Ritsema van Eck HJ, Boomsma F, Derkx FH, Schalenkamp MA (1992) Partial escape of agiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 10:803\u2013812","journal-title":"J Hypertens"},{"key":"789_CR69","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","volume":"37","author":"T Shiigai","year":"2001","unstructured":"Shiigai T, Shichiri M (2001) Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 37:477\u2013483","journal-title":"Am J Kidney Dis"},{"key":"789_CR70","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1097\/01.ASN.0000100145.27188.33","volume":"14","author":"WA Wilmer","year":"2003","unstructured":"Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA (2003) Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 14:3217\u20133232","journal-title":"J Am Soc Nephrol"},{"key":"789_CR71","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s00467-004-1451-y","volume":"19","author":"M Dyck Van","year":"2004","unstructured":"Van Dyck M, Proesmans W (2004) Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 19:688\u2013690","journal-title":"Pediatr Nephrol"},{"key":"789_CR72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-3476(03)00279-8","volume":"143","author":"D Ellis","year":"2003","unstructured":"Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE (2003) Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 143:89\u201397","journal-title":"J Pediatr"},{"key":"789_CR73","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1442-200x.2004.01955.x","volume":"46","author":"H Tanaka","year":"2004","unstructured":"Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576\u2013579","journal-title":"Pediatr Int"},{"key":"789_CR74","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/ndt\/gfm237","volume":"22","author":"G Ardissino","year":"2007","unstructured":"Ardissino G, Vigano S, Testa S, Dacco V, Paglialonga F, Leoni A, Belingheri M, Avolio L, Ciofani A, Claris-Appiani A, Cusi D, Edefonti A, Ammenti A, Cecconi M, Fede C, Ghio L, la Manna A, Maringhini S, Papalia T, Pela I, Pisanello L, Ratsch IM; ItalKid project (2007) No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy-report from the ItalKid Project database. Nephrol Dial Transplant 22:2525\u20132530","journal-title":"Nephrol Dial Transplant"},{"key":"789_CR75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","volume":"92","author":"WB White","year":"2003","unstructured":"White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W (2003) Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 92:38\u201342","journal-title":"Am J Cardiol"},{"key":"789_CR76","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"789_CR77","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","volume":"78","author":"The Randomized Aldactone Evaluation Study (RALES)","year":"1996","unstructured":"The Randomized Aldactone Evaluation Study (RALES) (1996) Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol 78:902\u2013907","journal-title":"Am J Cardiol"},{"key":"789_CR78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1291\/hypres.29.211","volume":"29","author":"A Sato","year":"2006","unstructured":"Sato A, Saruta T, Funder JW (2006) Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 29:211\u2013216","journal-title":"Hypertens Res"},{"key":"789_CR79","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","volume":"370","author":"S Oparil","year":"2007","unstructured":"Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 370:221\u2013229","journal-title":"Lancet"},{"key":"789_CR80","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941\u20131951","journal-title":"N Engl J Med"},{"key":"789_CR81","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0895-7061(00)00287-9","volume":"13","author":"H Kumagai","year":"2000","unstructured":"Kumagai H, Hayashi K, Kumamaru H, Saruta T (2000) Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: A one-year, prospective, randomized study. Am J Hypertens 13:980\u2013985","journal-title":"Am J Hypertens"},{"key":"789_CR82","first-page":"212","volume":"12","author":"F Marchi","year":"1995","unstructured":"Marchi F, Ciriello G (1995) Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 12:212\u2013221","journal-title":"Adv Ther"},{"key":"789_CR83","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1742-1241.1999.tb11793.x","volume":"53","author":"W Fassbinder","year":"1999","unstructured":"Fassbinder W, Quarder O, Waltz A (1999) Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicenter randomized study. Int J Clin Pract 53:519\u2013522","journal-title":"Int J Clin Pract"},{"key":"789_CR84","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","volume":"45","author":"TW Doulton","year":"2005","unstructured":"Doulton TW, He FJ, MacGregor FA (2005) Systemic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45:880\u2013886","journal-title":"Hypertension"},{"key":"789_CR85","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","volume":"63","author":"R Campbell","year":"2003","unstructured":"Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P (2003) Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63:1094\u20131103","journal-title":"Kidney Int"},{"key":"789_CR86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","volume":"48","author":"M MacKinnon","year":"2006","unstructured":"MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 48:8\u201320","journal-title":"Am J Kidney Dis"},{"key":"789_CR87","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1755.2002.00536.x","volume":"62","author":"GD Laverman","year":"2002","unstructured":"Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D (2002) Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62:1020\u20131025","journal-title":"Kidney Int"},{"key":"789_CR88","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","volume":"16","author":"RE Schmieder","year":"2005","unstructured":"Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16:3038\u20133045","journal-title":"J Am Soc Nephrol"},{"key":"789_CR89","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.mnh.0000174144.07174.74","volume":"14","author":"RC Hermida","year":"2005","unstructured":"Hermida RC, Diana EA, Calvo C (2005) Administration-time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr Opin Nephrol Hypertens 14:453\u2013459","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"789_CR90","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/hy1101.099502","volume":"38","author":"P Svensson","year":"2001","unstructured":"Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J (2001) Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 38:e28\u2013e32","journal-title":"Hypertension"},{"key":"789_CR91","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.HYP.0000174616.36290.fa","volume":"46","author":"RC Hermida","year":"2005","unstructured":"Hermida RC, Calvo C, Ayala DE, Lopez JE (2005) Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 46:960\u2013968","journal-title":"Hypertension"},{"key":"789_CR92","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1046\/j.1523-1755.1998.00865.x","volume":"53","author":"RH Mak","year":"1998","unstructured":"Mak RH (1998) 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53:1353\u20131357","journal-title":"Kidney Int"},{"key":"789_CR93","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s004670050524","volume":"12","author":"RH Mak","year":"1998","unstructured":"Mak RH (1998) Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol 12:660\u2013665","journal-title":"Pediatr Nephrol"},{"key":"789_CR94","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1523-1755.1998.00023.x","volume":"54","author":"RH Mak","year":"1998","unstructured":"Mak RH (1998) Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 54:603\u2013607","journal-title":"Kidney Int"},{"key":"789_CR95","first-page":"S1","volume":"Suppl 3","author":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group","year":"2003","unstructured":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group (2003) K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41(Suppl 3):S1\u2013S91","journal-title":"Am J Kidney Dis 41"},{"key":"789_CR96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2006.06.003","volume":"117","author":"H Holdaas","year":"2007","unstructured":"Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J (2007) The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double -blind, randomized trials. Int J Cardiol 117:64\u201374","journal-title":"Int J Cardiol"},{"key":"789_CR97","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JF, Ruf G, Ritz E, German study group for growth hormone treatment in chronic renal failure (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238\u2013248","journal-title":"N Engl J Med"},{"key":"789_CR98","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.ajkd.2004.08.040","volume":"45","author":"M Epstein","year":"2005","unstructured":"Epstein M, Campese VM (2005) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45:2\u201314","journal-title":"Am J Kidney Dis"},{"key":"789_CR99","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1046\/j.1523-1755.2002.00332.x","volume":"61","author":"C Zoja","year":"2002","unstructured":"Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G (2002) Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61:1635\u20131645","journal-title":"Kidney Int"},{"key":"789_CR100","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006\u20132016","journal-title":"J Am Soc Nephrol"},{"key":"789_CR101","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/01.ASN.0000135059.67385.5D","volume":"15","author":"EJ Sharples","year":"2004","unstructured":"Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Shaeff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, Yaqoob MM (2004) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15:2115\u20132124","journal-title":"J Am Soc Nephrol"},{"key":"789_CR102","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.ki.5002311","volume":"72","author":"N Eto","year":"2007","unstructured":"Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M (2007) Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 72:455\u2013463","journal-title":"Kidney Int"},{"key":"789_CR103","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1523-1755.2004.00797.x","volume":"66","author":"C Gouva","year":"2004","unstructured":"Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC (2004) Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 66:753\u2013760","journal-title":"Kidney Int"},{"key":"789_CR104","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Dr\u00fceke","year":"2006","unstructured":"Dr\u00fceke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071\u20132084","journal-title":"N Engl J Med"},{"key":"789_CR105","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1053\/j.ajkd.2006.08.023","volume":"48","author":"AS Levey","year":"2006","unstructured":"Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW, Collins AJ, Kopple JD (2006) Effect of dietary protein restriction on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 48:876\u2013888","journal-title":"Am J Kidney Dis"},{"key":"789_CR106","first-page":"CD001892","volume":"2","author":"D Fouque","year":"2000","unstructured":"Fouque D, Wang P, Laville M, Boissel JP (2000) Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. Cochrane Database Syst Rev (2):CD001892","journal-title":"Cochrane Database Syst Rev"},{"key":"789_CR107","first-page":"CD006863","volume":"4","author":"S Chaturvedi","year":"2007","unstructured":"Chaturvedi S, Jones C (2007) Protein restriction for children with chronic renal failure. Cochrane Database Syst Rev (4):CD006863","journal-title":"Cochrane Database Syst Rev"},{"key":"789_CR108","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","volume":"330","author":"S Klahr","year":"1994","unstructured":"Klahr S, Levy AD, Beck GJ (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877\u2013884","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"789_CR109","first-page":"S12","volume":"46","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation (2003) K\/DOQI Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46(Suppl 1):S12\u2013S100","journal-title":"Am J Kidney Dis"},{"key":"789_CR110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","volume":"110","author":"YC Li","year":"2002","unstructured":"Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P (2002) 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229\u2013238","journal-title":"J Clin Invest"},{"key":"789_CR111","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qui P, Williams L, Batlle W (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823\u20132828","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-008-0789-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-008-0789-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-008-0789-y.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-008-0789-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:22:11Z","timestamp":1708701731000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-008-0789-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s00467-008-0789-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}